Qinghua Ke

No. 10 Tianhu Road, Shashi District
Jingzhou, 434000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

H&E to recurrence score: A step forward, but not yet a substitute for genomic testing.

H&E to recurrence score: A step forward, but not yet a substitute for genomic testing.

Journal: Translational oncology

Published: June 04, 2026

Dual-targeting bispecific antibodies against extramedullary myeloma: A hypothesis-driven commentary.

Dual-targeting bispecific antibodies against extramedullary myeloma: A hypothesis-driven commentary.

Journal: Translational oncology

Published: May 08, 2026

When the tumor shrinks but the burden may persist: redefining therapeutic success in tenosynovial giant cell tumor.

When the tumor shrinks but the burden may persist: redefining therapeutic success in tenosynovial giant cell tumor.

Journal: Journal of cancer research and clinical oncology

Published: May 05, 2026

Stress, breast cancer, and the epigenetic echo: moving beyond the polygenic narrative?

Stress, breast cancer, and the epigenetic echo: moving beyond the polygenic narrative?

Journal: Frontiers in oncology

Published: April 25, 2026

Reconsidering the interpretation of dermoscopic criteria for acral lentiginous melanoma: dermoscopic features show promise, but real-world implementation faces unresolved barriers-a comment on Okwara et al.

Reconsidering the interpretation of dermoscopic criteria for acral lentiginous melanoma: dermoscopic features show promise, but real-world implementation faces unresolved barriers-a comment on Okwara et al.

Journal: Journal of cancer research and clinical oncology

Published: April 21, 2026

Universal CD7-targeted CAR T-cell therapy in T-ALL: a promising bridge to transplant, but not without caveats-a critical reappraisal.

Universal CD7-targeted CAR T-cell therapy in T-ALL: a promising bridge to transplant, but not without caveats-a critical reappraisal.

Journal: Frontiers in oncology

Published: April 15, 2026

PACIFIC-5 Trial: Refining Patient Selection for Consolidation Durvalumab in Unresectable Stage III NSCLC.

PACIFIC-5 Trial: Refining Patient Selection for Consolidation Durvalumab in Unresectable Stage III NSCLC.

Journal: Thoracic cancer

Published: April 11, 2026

Active surveillance for CIN2: biomarkers show promise, but real-world implementation faces unresolved barriers-a comment on Frayle et al.

Active surveillance for CIN2: biomarkers show promise, but real-world implementation faces unresolved barriers-a comment on Frayle et al.

Journal: Journal of cancer research and clinical oncology

Published: April 11, 2026

The SONIA trial: redefining "better" in the sequencing of CDK4/6 inhibitors for advanced breast cancer.

The SONIA trial: redefining "better" in the sequencing of CDK4/6 inhibitors for advanced breast cancer.

Journal: Frontiers in oncology

Published: March 14, 2026

Beyond dual targeting: redefining the treatment horizon for true extramedullary myeloma? - a critical appraisal.

Beyond dual targeting: redefining the treatment horizon for true extramedullary myeloma? - a critical appraisal.

Journal: Frontiers in oncology

Published: March 03, 2026

Epcoritamab plus R² in follicular lymphoma: practice-changing efficacy meets unresolved toxicity trade-offs.

Epcoritamab plus R² in follicular lymphoma: practice-changing efficacy meets unresolved toxicity trade-offs.

Journal: Frontiers in oncology

Published: February 15, 2026

The effects of recombinant human granulocyte colony-stimulating factor mouthwash on radiotherapy-induced oral mucositis in locally advanced nasopharyngeal carcinoma patients.

The effects of recombinant human granulocyte colony-stimulating factor mouthwash on radiotherapy-induced oral mucositis in locally advanced nasopharyngeal carcinoma patients.

Journal: Advances in clinical and experimental medicine : official organ Wroclaw Medical University

Published: August 10, 2017

Showing 1-12 of 13

Last Updated: 09/26/2026